Vaccinex, Inc. (VCNX)
USD 1.0
(66.67%)
USD 1.0
(66.67%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 26 Thousand USD | -89.47% |
| 2022 | 247 Thousand USD | 41.14% |
| 2021 | 175 Thousand USD | -84.57% |
| 2020 | 1.13 Million USD | 0.0% |
| 2019 | - USD | 0.0% |
| 2018 | - USD | -100.0% |
| 2017 | 2.81 Million USD | 171.26% |
| 2016 | 1.03 Million USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | - USD | -100.0% |
| 2024 Q1 | 6000.00 USD | -76.92% |
| 2023 Q2 | 125 Thousand USD | -32.43% |
| 2023 Q1 | 185 Thousand USD | -25.1% |
| 2023 FY | 26 Thousand USD | -89.47% |
| 2023 Q4 | 26 Thousand USD | -60.0% |
| 2023 Q3 | 65 Thousand USD | -48.0% |
| 2022 Q4 | 247 Thousand USD | -19.54% |
| 2022 Q3 | 307 Thousand USD | 122.46% |
| 2022 Q1 | 156 Thousand USD | -10.86% |
| 2022 FY | 247 Thousand USD | 41.14% |
| 2022 Q2 | 138 Thousand USD | -11.54% |
| 2021 Q3 | 1.13 Million USD | 0.0% |
| 2021 Q4 | 175 Thousand USD | -84.57% |
| 2021 Q1 | 1.13 Million USD | 0.0% |
| 2021 FY | 175 Thousand USD | -84.57% |
| 2021 Q2 | 1.13 Million USD | 0.0% |
| 2020 Q2 | 1.13 Million USD | 0.0% |
| 2020 Q4 | 1.13 Million USD | 0.0% |
| 2020 FY | 1.13 Million USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2020 Q3 | 1.13 Million USD | 0.0% |
| 2019 Q4 | - USD | 0.0% |
| 2019 Q2 | - USD | 0.0% |
| 2019 Q1 | - USD | 0.0% |
| 2019 FY | - USD | 0.0% |
| 2019 Q3 | - USD | 0.0% |
| 2018 Q1 | 1.22 Million USD | -56.35% |
| 2018 FY | - USD | -100.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q2 | - USD | -100.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q4 | 2.81 Million USD | 0.0% |
| 2017 FY | 2.81 Million USD | 171.26% |
| 2016 FY | 1.03 Million USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| America Great Health | 1.12 Million USD | 97.685% |
| Ampio Pharmaceuticals, Inc. | - USD | -Infinity% |
| Aridis Pharmaceuticals, Inc. | 1.29 Million USD | 97.988% |
| Biora Therapeutics, Inc. | 43.73 Million USD | 99.941% |
| Bio-Path Holdings, Inc. | 10 Thousand USD | -160.0% |
| Better Therapeutics, Inc. | 10.34 Million USD | 99.749% |
| Calithera Biosciences, Inc. | 136 Thousand USD | 80.882% |
| Comera Life Sciences Holdings, Inc. | 120.3 Thousand USD | 78.388% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | - USD | -Infinity% |
| Eloxx Pharmaceuticals, Inc. | 8.69 Million USD | 99.701% |
| Evelo Biosciences, Inc. | 48.87 Million USD | 99.947% |
| Evolutionary Genomics, Inc. | 3.74 Million USD | 99.306% |
| Finch Therapeutics Group, Inc. | 28.4 Million USD | 99.908% |
| Galera Therapeutics, Inc. | 151.04 Million USD | 99.983% |
| Innovation1 Biotech Inc. | 218.99 Thousand USD | 88.128% |
| Kiromic BioPharma, Inc. | 911.5 Thousand USD | 97.148% |
| Molecular Templates, Inc. | 9.74 Million USD | 99.733% |
| Navidea Biopharmaceuticals, Inc. | 1.87 Million USD | 98.611% |
| NexImmune, Inc. | - USD | -Infinity% |
| Orgenesis Inc. | 19.06 Million USD | 99.864% |
| Panbela Therapeutics, Inc. | 4.19 Million USD | 99.38% |
| Point of Care Nano-Technology, Inc. | - USD | -Infinity% |
| PaxMedica, Inc. Common Stock | - USD | -Infinity% |
| Scopus BioPharma Inc. | - USD | -Infinity% |
| Sorrento Therapeutics, Inc. | 104.33 Million USD | 99.975% |
| Statera Biopharma, Inc. | 11.43 Million USD | 99.773% |
| TRACON Pharmaceuticals, Inc. | 732 Thousand USD | 96.448% |
| Trevena, Inc. | 35.23 Million USD | 99.926% |
| Vaxxinity, Inc. | 13.26 Million USD | 99.804% |
| Vicapsys Life Sciences, Inc. | - USD | -Infinity% |
| Viracta Therapeutics, Inc. | - USD | -Infinity% |
| ZIVO Bioscience, Inc. | - USD | -Infinity% |